Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending that a marketing authorisation should not be granted for the orphan medicine voclosporin (Luveniq®), intended for the treatment of chronic non-infectious uveitis.
An accompanying Q&A document notes that the Committee was not convinced that the benefits of Luveniq had been shown to outweigh the risks as a treatment for chronic non-infectious uveitis and therefore recommended that it be refused marketing authorisation in the EU. Please see the link (Read more...)
Uncategorized